![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, August 26, 2013 10:10:58 AM
"Interesting. Why pick these particular companies from the list of 10,000 that you cite?
I don't know about the other two companies, but in the case of Celsion you are only telling a tiny part of the story, without any mention of their relationship with Hisun, or the VERY POSITIVE post-hoc trial subgroup results, which will be officially released in September at the most prestigious cancer conference in the world.
The P3 trial was poorly conceived by the FDA and Celsion. RF ablation times were not a control (independent) variable, and it needed to be. RFA also needed to be administered closer to an hour after infusion rather than the 15-45 minute window for this trial. There still is a LOT of potential for this delivery mechanism and framework.
Also, I believe your cash-burn rates are inflated by up to 50%. (They have enough cash to last 3-4 years at current burn rates.) And even so, the company has never had a problem raising funds.
So, the prospect for Celsion stock going to zero is just about zero."
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM